Angel rallies on ReNeuron deal

Angel Biotechnology rallied on news that the biopharmaceutical contract manufacturer signed a GMP manufacturing deal with ReNeuron.The value of the contract was not disclosed. The signing of deal follows on from ReNeuron's recent MHRA regulatory approval to commence a clinical trial with stem cell therapy for stroke. As ReNeuron's manufacturing partner, Angel will be manufacturing the stem cell clinical product for a Phase I clinical trial. "Angel is very pleased to have been chosen by ReNeuron to participate in their ground breaking clinical trial by manufacturing its ReN001 stem cell therapy in our GMP facilities," said chief operating officer Gordon Sherriff."Provision of the highest quality support for such advanced biological therapies is Angel's core competence and this contract firmly places Angel in the vanguard of this important and exciting development in medicinal therapy."